Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HART CT: Switching to Biktarvy for CV Risk in HIV
NCT03986697Phase 4Withdrawn
- Sponsor
- University of Liverpool
- Start
- Feb 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by University of Liverpool. Planned start Feb 2020; status: withdrawn.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03986697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03986697.